Shop

Showing 897–912 of 1319 results

Article: O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial
€3.03 Add to cart
Article: O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS
€3.03 Add to cart
Article: O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS
€3.03 Add to cart
Article: O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS
€3.03 Add to cart
Article: O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns
€3.03 Add to cart
Article: O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH
€3.03 Add to cart
Article: O.08 ULTRA-DEEP TARGETED RESEQUENCING REVEALS RECURRENT DAXX AND CYFIP2 MUTATIONS AND IMPLICATES NOVEL PATHWAYS IN PANCREATIC NEUROENDOCRINE TUMORS
€3.03 Add to cart
Article: O.09 Geriatric assessment (GA)- guided interventions in older patients (pts) with cancer
€3.03 Add to cart
Article: O.09 GLIOBLASTOMA MULTIFORME (GBM): STUPP AND REALITY
€3.03 Add to cart
Article: O.10 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials
€3.03 Add to cart
Article: O.10 THE DEUBIQUITINASE USP13 AS A NOVEL THERAPEUTIC CO-TARGET IN EGFR MUTANT NON-SMALL CELL LUNG CANCER
€3.03 Add to cart
Article: O.10 USP13 as a novel co-target for EGFR targeted therapies in EGFR mutant non-small cell lung cancer
€3.03 Add to cart
Article: O.11 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic review and meta-analysis
€3.03 Add to cart
Article: O.12 Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer
€3.03 Add to cart
Article: O.13 Colchicine as salvage for refractory pyrexia due to BRAF and MEK inhibitors: a case report
€3.03 Add to cart
Article: O.19 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020
€3.03 Add to cart

Article: O.05 Clinical significance of CD73 expression in triple-negative breast cancer from the BIG 02-98 adjuvant phase III clinical trial

Article: O.05 MT4-MMP, EGFR AND RB EXPRESSIONS ARE PREDICTIVE BIOMARKERS OF RESPONSE TO ERLOTINIB-PALBOCICLIB COMBINATION IN TRIPLE NEGATIVE BREAST CANCERS

Article: O.06 PHOTOBIOMODULATION THERAPY FOR THE PREVENTION OF ACUTE RADIATION DERMATITIS: PRELIMINARY RESULTS OF A RANDOMIZED, PLACEBO-CONTROLLED TRIAL IN BREAST CANCER PATIENTS

Article: O.07 EFFECT OF MINDFULNESS TRAINING ON QUALITY OF LIFE AND DISTRESS IN CANCER PATIENTS

Article: O.07 Mutational Landscaping of Liver Metastases with Desmoplastic and Replacement Growth Patterns

Article: O.08 Evaluation of HER2 expression and amplification in CTCs using CellSearch immunofluorescence and FISH

Article: O.08 ULTRA-DEEP TARGETED RESEQUENCING REVEALS RECURRENT DAXX AND CYFIP2 MUTATIONS AND IMPLICATES NOVEL PATHWAYS IN PANCREATIC NEUROENDOCRINE TUMORS

Article: O.09 Geriatric assessment (GA)- guided interventions in older patients (pts) with cancer

Article: O.09 GLIOBLASTOMA MULTIFORME (GBM): STUPP AND REALITY

Article: O.10 Cardiotoxicity of immune checkpoint inhibitors (ICI): a systematic review and meta-analysis of randomized clinical trials

Article: O.10 THE DEUBIQUITINASE USP13 AS A NOVEL THERAPEUTIC CO-TARGET IN EGFR MUTANT NON-SMALL CELL LUNG CANCER

Article: O.10 USP13 as a novel co-target for EGFR targeted therapies in EGFR mutant non-small cell lung cancer

Article: O.11 Cyclin dependent kinase inhibitors (CDK4-6i) as adjuvant treatment for patients (pts) with hormone receptor-positive (HR+)/HER2-negative (HER2-) early breast cancer (EBC): a systematic review and meta-analysis

Article: O.12 Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

Article: O.13 Colchicine as salvage for refractory pyrexia due to BRAF and MEK inhibitors: a case report

Article: O.19 Overall survival improvement in metastatic clear-cell renal cell carcinoma patients from 2000 to 2020